Allergan receives approval for Ozurdex
Multi-specialty healthcare company Allergan Inc announced that it has received approval from the FDA for Ozurdex 0.7 mg indicated for the treatment of the eye disease macular edema. Ozurdex is a first-of-its kind therapy dispensed by way of intravitreal injection delivering dexamethasone, a highly potent corticosteroid, through its proprietary and innovative Novadur solid polymer delivery system.


According to research by scientists at the Schepens Eye Research Institute, people with a certain low level of tear production have a higher probability of developing chronic dry eye syndrome after having undergone LASIK surgery. The laser refractive surgery is done to correct near- and far-sightedness. The study, published in Investigative Ophthalmology and Vision Science, may help ophthalmologists find out if these patients require pretreatment and whether or not surgery is appropriate for such persons.